At Texas Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options. As a member of US Oncology Research, we are pleased to share this list of Phase I - IV clinical trials currently enrolling at Texas Oncology-Fort Worth.

PHASE I CLINICAL TRIALS

BREAST/LUNG
• A Phase Ib Open Label, Dose Escalation study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with Her2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer (NSCLC)

SOLID TUMOR
• A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies (Ovarian cancer, triple negative breast cancer, NSCLC, melanoma, mesothelioma, small cell lung cancer, prostate, bladder, cholangio, and HCC)

PHASE II-IV CLINICAL TRIALS

BRAIN
• Randomized Phase II Trial Of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant And Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

BREAST
• A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease
• Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis
• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without LY2835219, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
• A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
• A Phase III randomized, double blind, placebo controlled study of BMK120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
• Randomized Phase II Trial of Chemotherapy of Physician’s Choice Plus Trastuzumab Versus Chemotherapy of Physician’s Choice Plus Trastuzumab Plus Pertuzumab in Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer
• A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

CERVICAL
• A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone

HEAD & NECK
• A Phase III study of postoperative radiation therapy (IMRT) +/- Cetuximab for locally advanced resected Head & Neck Cancer

HEMATOLOGIC/SOLID TUMOR -TARGETED THERAPY
• Modular Phase II study to link targeted therapy to patients with pathway activated tumors: Module 3 - MEK162 for patients with RAS/RAF/MEK activated tumors
• Modular Phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
• Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 6 – BGJ398 for Patients With Tumors With FGFR Genetic Alterations
• Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1
• Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors

For more information or to refer a patient, please call (817) 850-2010.

Trial listing current as of February 2015.
LEUKEMIA
• A Phase III, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

LUNG
• Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer
• A Phase III, multicenter, randomized, open-label study of oral LDK378 (Ceritinib) versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib

LYMPHOMA
• A Phase II open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

OVARIAN
• A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAEL YX® With DOXIL®/CAEL YX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

PANCREATIC
• A Randomized, Double-Blind, Phase III Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or are Intolerant to First-Line Chemotherapy
• A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer

PROSTATE
• A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
• A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

RENAI
• A Randomized, Phase II Study to Assess the Safety and Efficacy of CRLX101 in Combination with Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (RCC) versus Standard of Care
• A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib

To search all clinical trials currently enrolling at Texas Oncology, please visit, www.TexasOncology.com/Clinical-Trials/